Company RemeGen Co., Ltd.

Equities

9995

CNE1000048G6

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Ratings for RemeGen Co., Ltd.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Delayed Hong Kong S.E. Other stock markets 10:51:20 29/04/2024 am IST			5-day change	1st Jan Change
27.65 ^HKD	-9.34%		-2.47%	-26.17%

26/04	RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04/04	Remegen Gets US FDA Fast Track Designation for Primary Sjögren's Syndrome Medication	MT

RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The Company is mainly engaged in the discovery, development and commercialization of therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company's main products include tetacept (RC18), veldicitumab (RC48) and dual-target fusion protein (RC28). The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly conducts its businesses in the domestic market.

Number of employees: 3,615

HKD in Million	2022	Weight	2023	Weight	Delta
Biopharmaceutical Research, Service and Production 100.0 %	-	-	1,189	100.0 %	-

HKD in Million	2022	Weight	2023	Weight	Delta
China 97.5 %	843	94.1 %	1,159	97.5 %	+37.60%
United States 2.5 %	53	5.9 %	30	2.5 %	-43.64%

Managers	Title	Age	Since
Jian Min Fang CEO	Chief Executive Officer	62	04/08/04
Shao Jing Tong DFI	Director of Finance/CFO	53	28/23/28
Ruyi He CTO	Chief Tech/Sci/R&D Officer	63	11/20/11
Wei Liang IRC	Investor Relations Contact	41	-
Pak Yu Tam SEC	Corporate Secretary	-	11/20/11

Members of the board	Title	Age	Since
Xian Jing Hao BRD	Director/Board Member	59	11/20/11
Jian Min Fang CEO	Chief Executive Officer	62	04/08/04
Ruyi He CTO	Chief Tech/Sci/R&D Officer	63	11/20/11
Jian Lin BRD	Director/Board Member	69	04/08/04
Liqiang Wang BRD	Director/Board Member	54	11/20/11
Xiaodi Su BRD	Director/Board Member	38	11/20/11
Wei Dong Wang FOU	Founder	65	04/08/04
Ren Guangke CHM	Chairman	51	11/20/11
Li Yupeng BRD	Director/Board Member	41	11/20/11
Li Zhuan Glin BRD	Director/Board Member	50	11/20/11

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	354,750,844	135,780,346 ( 38.27 %)	0	55.32 %
Stock B	1	189,581,239	165,352,198 ( 87.22 %)	4,076,333 ( 2.150 %)

Name	Equities	%	Valuation
Jian Min Fang 12.79 %	24,244,500	12.79 %	84 M $
E Fund Management Co., Ltd. 8.359 %	15,846,630	8.359 %	55 M $
GF Fund Management Co., Ltd. 1.893 %	3,589,500	1.893 %	12 M $
Wei Dong Wang 1.891 %	3,584,541	1.891 %	12 M $
Penghua Fund Management Co., Ltd. 1.462 %	2,771,000	1.462 %	10 M $
Zheshang Fund Management Co., Ltd. 1.281 %	2,428,000	1.281 %	8 M $
Zhong Ou Asset Management Co., Ltd 1.095 %	2,075,000	1.095 %	7 M $
Bosera Asset Management Co., Ltd. 1.017 %	1,928,500	1.017 %	7 M $
Ruyi He 0.8465 %	1,604,840	0.8465 %	6 M $
Franklin Templeton Sealand Fund Management Co., Ltd. 0.5744 %	1,089,000	0.5744 %	4 M $

Name	Equities	%	Valuation
SDIC Venture Capital Co. Ltd. 15.75 %	25,238,279	15.75 %	188 M $
PAG (Hong Kong) 9.408 %	15,076,145	9.408 %	112 M $
Shenzhen Capital Group Co., Ltd. 7.996 %	12,813,478	7.996 %	96 M $
GF Fund Management Co., Ltd. 4.948 %	7,929,433	4.948 %	59 M $
Hong Tu Zhu 4.897 %	7,846,855	4.897 %	58 M $
Penghua Fund Management Co., Ltd. 3.798 %	6,086,685	3.798 %	45 M $
Huatai Securities (Shanghai) Asset Management Co., Ltd. 3.396 %	5,442,630	3.396 %	41 M $
Fullgoal Fund Management Co., Ltd. 2.821 %	4,520,161	2.821 %	34 M $
LU THAI TEXTILE CO., LTD. 2.632 %	4,218,265	2.632 %	31 M $
Wei Dong Wang 2.566 %	4,111,338	2.566 %	31 M $

RemeGen Co., Ltd.

No. 58, Beijing Middle Road Yantai Development Zone

264006, Yantai

+86 53 5611 3513

http://www.remegen.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

28.23 CNY

Average target price

40.14 CNY

Spread / Average Target

+42.16%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
REMEGEN CO., LTD.	-25.63%	3.48B
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs